urea has been researched along with Movement Disorders in 6 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although there are no approved drugs for treating psychotic symptoms in any of the movement disorders, pimavanserin, a 5-HT2A inverse agonist, is thought likely to gain approval in 2015 for treating PD psychosis." | 4.90 | Treating psychosis in movement disorder patients: a review. ( Borek, LL; Friedman, JH, 2014) |
| "In addition, genetic analysis for Dravet syndrome showed the presence of heterozygous disease-causing mutation SCN1A NM_001165963." | 1.42 | NMR-based urinalysis for rapid diagnosis of β-ureidopropionase deficiency in a patient with Dravet syndrome. ( Chan, B; Chan, KY; Lai, CK; Lam, CW; Law, CY; Leung, KF; Mak, CM; Pak-lam Chen, S; Yan-wo Chan, A; Yuen, YP, 2015) |
| "Spinal cord ischemia was induced by intraaortic balloon occlusion combined with proximal arterial hypotension for 10 minutes." | 1.36 | Esmolol and landiolol, selective beta1-adrenoreceptor antagonists, provide neuroprotection against spinal cord ischemia and reperfusion in rats. ( Goyagi, T; Masaki, Y; Nishikawa, T; Tobe, Y; Umehara, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mahajan, A | 1 |
| Bulica, B | 1 |
| Ahmad, A | 1 |
| Kaminski, P | 1 |
| LeWitt, P | 1 |
| Taylor, D | 1 |
| Krstevska, S | 1 |
| Patel, N | 1 |
| Borek, LL | 1 |
| Friedman, JH | 1 |
| Lam, CW | 1 |
| Law, CY | 1 |
| Leung, KF | 1 |
| Lai, CK | 1 |
| Pak-lam Chen, S | 1 |
| Chan, B | 1 |
| Chan, KY | 1 |
| Yuen, YP | 1 |
| Mak, CM | 1 |
| Yan-wo Chan, A | 1 |
| Umehara, S | 1 |
| Goyagi, T | 1 |
| Nishikawa, T | 1 |
| Tobe, Y | 1 |
| Masaki, Y | 1 |
| ROUSSINOV, K | 1 |
| Turova, NF | 1 |
| Ermolina, LA | 1 |
| Baryshnikov, VA | 1 |
1 review available for urea and Movement Disorders
| Article | Year |
|---|---|
Treating psychosis in movement disorder patients: a review.
Topics: Animals; Antipsychotic Agents; Clozapine; Humans; Movement Disorders; Piperidines; Psychotic Disorde | 2014 |
5 other studies available for urea and Movement Disorders
| Article | Year |
|---|---|
Pimavanserin use in a movement disorders clinic: a single-center experience.
Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Movement Disorders; P | 2018 |
NMR-based urinalysis for rapid diagnosis of β-ureidopropionase deficiency in a patient with Dravet syndrome.
Topics: Abnormalities, Multiple; Amidohydrolases; beta-Alanine; Brain Diseases; Epilepsies, Myoclonic; Gas C | 2015 |
Esmolol and landiolol, selective beta1-adrenoreceptor antagonists, provide neuroprotection against spinal cord ischemia and reperfusion in rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Blood Gas Analysis; He | 2010 |
ON CERTAIN CORRELATIONS OF THE ANTICONVULSIVE DRUGS PHENYLCARBAMIDE, META-TOLYLCARBAMIDE AND PHENURONE WITH CHOLINERGIC AND ADRENERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM.
Topics: Adrenergic Agents; Animals; Anticonvulsants; Benzeneacetamides; Cholinergic Agents; Mice; Movement D | 1964 |
[Characteristics of the amino acid spectrum of the blood of children with intellectual deficiency].
Topics: Amino Acids; Ammonia; Arginine; Aspartic Acid; Child; Female; Glutamates; Glutamic Acid; Humans; Int | 1986 |